European heart journal. Digital health · 2026
Proteomic phenotyping with machine learning for cardiovascular outcomes in haemodialysis: insights from the AURORA trial.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Salib Madonna, Girerd Sophie, Pinet Florence, März Winfried, Scharnagl Hubert, Massy Ziad A, Leroy Celine, Duarte Kevin, Bresso Emmanuel, Lacomblez Claire, Jardine Alan G, Schmieder Roland E, Fellstrom Bengt, Lopez-Andres Natalia, Rossignol Patrick, Zannad Faiez, Girerd Nicolas
Аннотация
AIMS: Cardiovascular (CV) trials have yielded neutral results in haemodialysis. A better understanding of patient profiles is needed to personalize treatment strategies in order to improve CV outcomes in this setting. This study sought to identify biological phenotypes based on proteomic data using machine learning approaches in patients undergoing haemodialysis.
METHODS AND RESULTS: A clustering analysis using 253 plasma protein biomarkers was performed in 382 patients (machine learning derivation analysis) from the AURORA trial, which tested the effect of rosuvastatin on CV outcomes in patients on haemodialysis. A decision tree was subsequently constructed to predict cluster membership and assess its association with CV outcomes in another subset of the trial (n = 389 patients, validation analysis). Four phenotypes were identified, namely 'cytokine storm signalling', 'toll-like receptors (TLRs) signalling', 'multiple pathways related to inflammation and fibrosis' phenotypes, as well as a 'reference phenotype' which exhibited the least biological abnormalities. In multivariable analysis of the validation study, after adjusting for key prognostic factors, the TLRs phenotype was significantly associated with CV death, all-cause mortality, and MACE (HR = 1.65 [1.13-2.41], 1.43 [1.03-1.98], and 1.48 [1.04-2.10], respectively).
CONCLUSION: Using unsupervised machine learning on proteomic data, we identified four mechanistic biological phenotypes involving cytokine storm and TLRs signalling, inflammation and fibrosis. These biological phenotypes may contribute to CV prognosis and pave the way for personalized therapy in haemodialysis.
METHODS AND RESULTS: A clustering analysis using 253 plasma protein biomarkers was performed in 382 patients (machine learning derivation analysis) from the AURORA trial, which tested the effect of rosuvastatin on CV outcomes in patients on haemodialysis. A decision tree was subsequently constructed to predict cluster membership and assess its association with CV outcomes in another subset of the trial (n = 389 patients, validation analysis). Four phenotypes were identified, namely 'cytokine storm signalling', 'toll-like receptors (TLRs) signalling', 'multiple pathways related to inflammation and fibrosis' phenotypes, as well as a 'reference phenotype' which exhibited the least biological abnormalities. In multivariable analysis of the validation study, after adjusting for key prognostic factors, the TLRs phenotype was significantly associated with CV death, all-cause mortality, and MACE (HR = 1.65 [1.13-2.41], 1.43 [1.03-1.98], and 1.48 [1.04-2.10], respectively).
CONCLUSION: Using unsupervised machine learning on proteomic data, we identified four mechanistic biological phenotypes involving cytokine storm and TLRs signalling, inflammation and fibrosis. These biological phenotypes may contribute to CV prognosis and pave the way for personalized therapy in haemodialysis.